Kilter Group’s Janux Therapeutics JANX Stock Holding History

Kilter Group’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23	Closed	-$320	–	1647
2026 Q1	$320	Buy	+23	New	+$315	﹤0.01%	1428

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Kilter Group's JANX Position: Q2 2026 in Review

Kilter Group sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 23 shares — an estimated $320 sold.

Kilter Group first reported a position in JANX in Q1 2026 and held it in 1 quarter. The position peaked at $320 in Q1 2026. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Kilter Group reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
Kilter Group sold 23 Janux Therapeutics shares in Q2 2026, an estimated $320.
Kilter Group first reported a position in Janux Therapeutics in Q1 2026 and held it in 1 quarter.
Kilter Group's Janux Therapeutics position peaked at $320 in Q1 2026.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.